Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.
The assay relies on detection of a fungal disaccharide in patient serum and showed performance that was comparable and complementary to existing diagnostics.
The company, which has struggled to turn its broad proteomics expertise into steady profits, plans to focus more tightly on its pharma services business.
The researchers built a three-protein panel that identified patients who developed Alzheimer's disease with a sensitivity of 80 percent and specificity of 79 percent.
The company expects its purchase of ImmuneHealth's immune monitoring laboratory will help it win business for clinical work requiring fresh sample analysis.
The researchers said the work provides insights into the dimethyl fumarate's mode of action and identifies potential new drug targets for diseases like multiple sclerosis.
The study found a broader role for the modification in cellular functions than previously identified, including potential links to processes involved in cancer.
The group this week published a set of initial guidelines for antibody validation meant as recommendations in advance of a larger meeting later this month.
